Xiamen Amoytop Biotech Co., Ltd.
688278.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.72B
Close$
$91.42
83.2% upside
Current Fair Value
83.2% upsideUndervalued by 83.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.72 Billion |
|---|---|
| Enterprise Value | $20.71 Billion |
| Dividend Yield | $0.62 (1.22%) |
| Earnings per Share | $2.53 |
| Beta | -0.13 |
| Outstanding Shares | 406,814,348 |
Return
| Return on Equity | 34.79% |
|---|---|
| Return on Assets | 24.02% |
| Return on Invested Capital | 32.24% |
Valuation & Multiples
| P/E Ratio | 19.23 |
|---|---|
| PEG | 71.32 |
| Price to Sales | 5.55 |
| Price to Book Ratio | 7.13 |
| Enterprise Value to Revenue | 5.15 |
| Enterprise Value to EBIT | 16.44 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$0.65
Average shareholder expectationRevenue Estimate
$997.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
$0.65
Average shareholder expectationRevenue Estimate
$1.15 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Xiamen Amoytop Biotech Co., Ltd.
3,640 employees
CEO: Li Sun Xiamen Amoytop Biotech Co., Ltd. specializes in the creation, commercialization, and distribution of biopharmaceutical products within China, utilizing advanced genetic engineering techniques. Its offerings span a variety of pharmaceutic...